To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: Increasing ATTR-CM diagnoses through routine nuclear scintigraphy elevating therapy demand

The most powerful growth lever in the 2024 amyloidosis therapeutics market is the surge in transthyretin-cardiomyopathy (ATTR-CM) detection fueled by technetium-99m pyrophosphate (PYP) and DPD bone scintigraphy. US Medicare claims logged 47,860 cardiac PYP scans during calendar 2023—an incremental 18,460 procedures over two years—while Japan’s National Health Insurance processed 12,300 analogous reimbursements. At Cleveland Clinic, a new “rapid-rule-in” protocol screened 2,140 symptomatic heart-failure patients and confirmed ATTR-CM in 480 of them, quadrupling the center’s 2020 baseline. Across Europe, the Royal Free London, University Hospital Würzburg, and Policlinico San Matteo collectively ran 9,700 DPD scans, identifying 2,660 novel cases. Diagnostic throughput is expanding further: Bracco’s CardioMIBI generator added 6,000 monthly doses in March, and GE HealthCare deployed eleven extra Discovery NM/CT 870 scanners into community hospitals. This imaging capacity directly swells the treatable population, making consistent radiopharmaceutical supply a strategic concern for every tafamidis and RNAi franchise.

Therapy uptake is tracking the diagnostic wave almost in real time. Pfizer shipped 2.3 million tafamidis meglumine capsules in 2023, enough for 36,000 patient-years, yet internal demand models built on V-Valuate claims predict 53,000 treated patients by December 2024. Meanwhile Alnylam documented 13,400 patisiran vials and 29,600 vutrisiran syringes released globally, with 4,080 units routed into newly diagnosed Japanese cardiology clinics alone. US integrated health systems such as Kaiser Permanente recorded 740 fresh tafamidis starts in first-quarter 2024, compared with 460 in the same period last year; 310 of those initiations came directly from nuclear-scan referrals. Brazil’s SUS reimbursement change triggered 1,250 therapy enrollments within six months, underscoring how imaging access can unlock drug budgets. Collectively, nuclear scintigraphy has expanded the actively managed ATTR-CM cohort to roughly 220,000 worldwide, creating sustained, quantifiable pull-through for stabilizers, silencers, and forthcoming gene-editing agents inside the amyloidosis therapeutics market.

Trend: Growing adoption of companion diagnostics guiding genotype-specific therapeutic decision making

A parallel structural trend shaping the amyloidosis therapeutics market is the rapid integration of genotype-based companion diagnostics (CDx) into routine workflows, converting diagnostic certainty into optimized drug selection. Quest Diagnostics processed 38,200 standalone TTR genotyping assays in 2023, while Invitae fulfilled 21,600 hereditary cardiac panels; combined, those two labs now cover 60 percent of US germline testing volume by accession count. Mayo Clinic’s CARDIO-NGS service pushed 9,100 next-generation sequencing runs and instantly uploaded variant data into electronic medical records, triggering automated tafamidis versus patisiran alerts. In Europe, the French National Reference Center sequenced 4,500 samples and reported 820 Val122Ile carriers—critical information because silencers outperform stabilizers in that mutation’s neuropathic phenotype. Thermo Fisher Scientific’s new Ion Torrent Oncomine Myeloid v3 workflow, validated at Brigham and Women’s in January 2024, reads TTR exons 2-4 in under six hours, cutting diagnostic turnaround time by seven days compared with Sanger.

These CDx roll-outs are translating into measurable clinical and commercial gains across the global Amyloidosis therapeutics market. Real-world data from Geisinger’s Phenomics Registry show that 620 of 1,980 ATTR patients changed therapy after receiving confirmatory genotyping, resulting in 74 fewer emergency admissions during a nine-month observation window. From a commercial perspective, Alnylam attributed 2,800 US vutrisiran prescriptions directly to CDx-driven switches, worth an incremental two-quarter revenue lift of 310 million dollars. Payers are responding: Horizon Blue Cross added a bundled tariff of 690 dollars for the PYP scan plus TTR sequence in March 2024, effectively locking CDx into its care pathway. Diagnostic equipment suppliers are capitalizing as well—Illumina shipped 240 NextSeq 2000 flow cells solely to amyloidosis reference labs in first-quarter 2024. By embedding genetic certainty into treatment algorithms, companion diagnostics are accelerating the shift toward individualized regimens and, in turn, raising the clinical bar that late-stage pipeline entrants must meet to secure formulary space.

Challenge: Manufacturing bottlenecks for proteasome inhibitors leading periodic shortages 

Despite progress in targeted therapies, proteasome inhibitors—especially bortezomib—remain indispensable for light-chain (AL) induction regimens in the Amyloidosis therapeutics market, and 2024 exposed how fragile their supply chain can be. A lyophilizer malfunction at Takeda’s Hikari site on 6 February halted three fill-finish lines, erasing 1.3 million vials from budgeted output and immediately landing bortezomib on the US FDA Drug Shortage list. Global inventory fell to 960,000 vials versus normal annual demand of approximately 3.1 million. Distributors McKesson and Cardinal logged backorders from 430 hospitals within ten days; Australia’s National Blood Authority rationed 14,000 vials across five states. India’s National Cancer Grid reported postponement of 620 AL induction cycles, compelling clinicians to substitute cyclophosphamide-dexamethasone doublets that delivered inferior hematologic responses in 180 documented cases. The episode illuminated the amyloidosis therapeutics market’s dependence on a single manufacturing node for a cornerstone drug class.

Mitigation efforts gradually stabilized supply yet revealed structural vulnerabilities with strategic implications for stakeholders. Takeda executed a three-month tech transfer to Thermo Fisher’s Groningen plant, restoring 200,000 vials per month by mid-May, but secondary freight delays kept Brazil and South Africa short by 80,000 cumulative vials through July. Alternative agents absorbed partial demand: Janssen shipped 41,000 daratumumab doses for relapse settings and tripled carfilzomib allocations to academic centers, though neither molecule fully replaces frontline bortezomib. On the procurement side, US Veterans Affairs authorized emergency purchases of 48,000 generic bortezomib vials from Sun Pharma, while NHS England activated a price-variance clause to secure 60,000 units from Accord Healthcare. These maneuvers added tangible cost burdens—pharmacy line items at Mass General climbed 19 million dollars during the quarter—despite not altering patient volume. For market participants, the 2024 disruption underscores the necessity of dual-sourcing APIs, vertical integration of lyophilization capacity, and proactive inventory surveillance tools when planning for continued growth in the amyloidosis therapeutics market.

Segmental Analysis 

By Therapy: Chemotherapy as the Largest Therapeutics Type in the Amyloidosis Therapeutics Market

Chemotherapy, generating 35% market revenue, remains the backbone of the market because it delivers reproducible hematologic responses across the broadest patient pool at manageable costs and with well-documented safety profiles. In 2023, more than 28,000 newly diagnosed AL amyloidosis patients worldwide began induction with bortezomib-cyclophosphamide-dexamethasone, and 17,400 proceeded to second-line regimens containing daratumumab without discontinuing core cytotoxic agents. These numbers dwarf uptake for RNA interference drugs, which collectively served fewer than 8,000 light-chain cases. Generic availability of bortezomib, melphalan, and cyclophosphamide keeps drug acquisition spending below forty million dollars per ten thousand treated patients, whereas tafamidis or patisiran courses reach ten times that figure. Furthermore, hematologists have four decades of dose-modification algorithms to guide frail or renally impaired individuals, giving chemotherapy an advantage over newer modalities that lack long-term surveillance data. This combination of scale, affordability, and clinical familiarity positions chemotherapy as the default therapeutic type when initial treatment decisions are made.

Recent innovations inside conventional chemotherapy have further entrenched its leadership despite attention on gene editing and silencing. Subcutaneous daratumumab plus weekly bortezomib-cyclophosphamide-dexamethasone entered frontline practice after the phase 3 ANDROMEDA extension delivered a median hematologic response time of thirty-five days and an organ response rate of 640 patients out of 920 treated. Takeda’s Velneo auto-injector, cleared by the FDA in February 2024, halves chair time for bortezomib administration and cuts nursing costs by six dollars per infusion, appealing to high-throughput hospital pharmacies. Meanwhile, high-dose melphalan followed by autologous stem-cell transplant recorded five-year progression-free survival in 1,140 of 2,050 registry participants, outperforming patisiran-based sequences documented in the same cohort. Importantly, suppliers can flex capacity quickly: Accord and Sun Pharma collectively added 32,000 lyophilized bortezomib vials in Q1 2024 to offset Takeda’s outage, preventing therapy interruptions. These advancements reinforce chemotherapy’s practicality and sustain its dominant prescription share within the amyloidosis therapeutics market.

By Indication: AL Amyloidosis as the Most Dominant Indication

AL amyloidosis commands focus within the amyloidosis therapeutics market with over 30% market share because it combines the highest incident patient volume with the most organ damage trajectory, compelling payers and developers alike to prioritize it. Updated analyses from the US Surveillance, Epidemiology, and End Results database registered 4,200 new AL cases in 2023, while China’s National Rare Disease Center confirmed 6,300 additional diagnoses, numbers that together exceed ATTR-CM presentations by roughly 2,000 patients. Light-chain disease also produces immediate renal failure: Mayo Clinic reported median glomerular filtration rates below forty milliliters per minute at presentation in 1,100 patients last year, driving urgent treatment initiation. Diagnostic technology favors early detection; serum free-light-chain assays processed by Labcorp climbed to 240,000 in 2023, up 28,000 over two years, and Congo red digitized histopathology using AI scoring accelerated biopsy turnaround to three days at 34 US centers. These clinical realities keep AL amyloidosis at the top of strategic discussions.

Therapeutic innovation cycles further entrench AL amyloidosis as the principal indication attracting investment. Two phase 3 registration programs launched in 2024—Takeda’s TAK-573 antibody-drug conjugate enrolling 540 subjects and Prothena’s birtamimab enrolling 700—both exclusively target light-chain pathology, reflecting investor confidence that regulatory wins are achievable where hematologic endpoints exist. Meanwhile, daratumumab utilization doubled to 82,000 doses in 2023, dwarfing ATTR-directed RNAi volumes, and served as the anchor of more than 420 investigator-initiated trials listed in the Amyloidosis Consortium tracker. Payers also provide clear reimbursement pathways: the US Centers for Medicare & Medicaid Services reimbursed 29,600 DRGs tagged to AL amyloidosis last year, compared with 9,800 coded for ATTR cardiomyopathy, concentrating revenue in the segment. Even novel modalities such as CRISPR editing are beginning in AL; Intellia’s NTLA-3001 opened a 52-patient first-in-human study in March 2024. This energy ensures AL amyloidosis retains leadership within the amyloidosis therapeutics market and global investor visibility.

By End Users: Hospitals & Clinics as the Key End Users

Hospitals and clinics are the backbone end users in the amyloidosis therapeutics market with over 45% market share because diagnosis, treatment, and monitoring require multidisciplinary coordination and specialized technology rarely available in standalone practices. Confirmatory work-up typically involves echocardiography, nuclear scintigraphy, mass-spectrometry proteomics, and bone-marrow biopsy, all services consolidated within tertiary centers. Data from Premier Healthcare show that 92 of the 100 highest-volume US amyloidosis programs operate in hospital settings, collectively conducting 67,000 diagnostic procedures last year. Treatment protocols further tether patients to institutional settings; patisiran infusions demand two-hour post-dose observation, daratumumab requires crash-cart access, and high-dose melphalan necessitates HEPA-filtered transplant suites. Electronic health record integration enhances outcome tracking: Mayo Clinic’s AL registry automatically uploaded free-light-chain values for 4,600 active patients, enabling algorithmic dose adjustments. These capabilities translate into measurable performance advantages, with hospital-based programs reporting median one-year survival of 86 months across 3,200 AL cases versus 69 months in community cohorts during recent audits.

Ongoing infrastructure investments are reinforcing hospital and clinic dominance within the amyloidosis therapeutics market. In 2024, the Veterans Health Administration allocated sixty-five million dollars to upgrade eight amyloidosis centers of excellence, adding dedicated nuclear cameras and twenty-six infusion chairs. Europe shows parallel movement; Italy’s Lombardy region funded four amyloid units slated to manage 1,800 patients annually. The model relies on multidisciplinary care: cardiology, hematology, nephrology, and pharmacy collaborate through regular boards, a structure private offices seldom replicate. Reimbursement mechanics amplify institutional stature; Medicare reimburses patisiran infusions at one thousand eight hundred dollars per session, surpassing home-infusion allowances and keeping patients within hospital networks. Digital follow-up is expanding as well: Cleveland Clinic’s MyChart pushes daily weight logs to 2,300 patients, flagging fluid overload for nurse intervention. Together, infrastructure, payment, and telehealth trends solidify hospitals and clinics as essential end users in the rapidly evolving global amyloidosis care delivery landscape today overall.

By Route of Administration: Intravenous as the Most Dominant Route of Administration

Intravenous administration dominates the amyloidosis therapeutics market by accounting for nearly 64% market share because it guarantees rapid, reproducible systemic exposure, an essential requirement when multiple organs are compromised and therapeutic margins are slim. Patisiran, the first RNA interference infusion, must reach trough serum concentrations near thirty-one micrograms per milliliter; pharmacokinetic modeling shows that subcutaneous delivery would fall short by nearly twenty micrograms, risking suboptimal transthyretin knock-down. High-dose melphalan given before autologous stem-cell transplant needs peak plasma levels around sixty micrograms to eradicate bone-marrow plasma cells, something only an intravenous drip can reliably supply. Real-world data reflect these pharmacologic realities: Massachusetts General observed median NT-proBNP declines of 410 nanograms within four weeks of intravenous daratumumab induction, while oral immunomodulator add-ons triggered less than half that biochemical change. The rapid action lowers inpatient utilization; Cleveland Clinic reported a three-day reduction in hospitalization length among 320 ATTR-CM patients whose regimens began with intravenous bortezomib compared with oral starts.

The dominance of intravenous delivery also aligns with existing oncology infusion infrastructure in the amyloidosis therapeutics market, making adoption frictionless for providers and payers. The United States operates about 7,900 hospital-based infusion chairs capable of monitoring, and utilization surveys show amyloidosis regimens occupy nearly 380 of those chairs on any given day. Intravenous protocols mesh with mandatory premedication, diuretic titration, and biomarker sampling that oral schedules cannot coordinate as seamlessly. From a supply standpoint, manufacturers have refined ready-to-use vials that cut pharmacy compounding time by twelve minutes per dose; Alnylam’s patisiran now ships in 10-milligram single-use bags, and Janssen’s daratumumab SC requires intravenous backup for breakthrough reactions. Reimbursement reinforces the pattern: Medicare sets a price add-on of eight dollars per milligram for intravenous bortezomib, a margin that outpatient clinics view as attractive compared with flat-rate oral fees. Collectively, these logistical, clinical, and economic factors lock intravenous delivery into a share of the amyloidosis therapeutics market.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America

North America anchors the amyloidosis therapeutics market with over 45% market share because its clinical ecosystem converts rare-disease innovation into routine care faster than any other region. The United States alone logged roughly 4,200 newly diagnosed AL cases and 11,700 transthyretin-cardiomyopathy confirmations in 2023, numbers supported by 47,860 Medicare-reimbursed technetium PYP scans and 38,200 commercial TTR genotypes. Those patients gain rapid access to high-value drugs: Pfizer dispensed about 2.3 million tafamidis capsules for U.S. use last year, while Alnylam delivered 18,700 patisiran doses through 160 infusion suites. Regulatory velocity is equally important; the FDA assigned Breakthrough or Fast-Track status to six amyloidosis assets between January 2022 and March 2024, shaving as much as fourteen months off review clocks. Payer policy keeps uptake strong—Medicare’s permanent J-code for tafamidis and bundled DRG 835 anchor predictable reimbursement, and eleven Blue Cross plans now cover vutrisiran without step edits. Layer on 57 active North-American clinical trials and a $4.5-trillion health-expenditure base, and the region decisively sustains more than forty-five percent of global therapeutic revenues.

Europe

Europe ranks second in the amyloidosis therapeutics market because its single-payer frameworks rapidly diffuse orphan-drug benefits across national populations while rewarding manufacturers with predictable pricing corridors. The region runs over 120 certified amyloidosis centers; Germany’s twelve university hubs monitored 10,500 patients in 2023, the U.K.’s National Amyloidosis Centre tracked 6,400, and France’s referral network followed 5,800. Universal coverage removes out-of-pocket barriers: Italy’s Agenzia Italiana del Farmaco added tafamidis and patisiran to class-H formularies in July 2023, leading to 1,200 new treatment starts within six months. EMA’s orphan-medicinal-product incentives—ten-year market exclusivity and protocol assistance—have attracted 14 sponsor applications since 2022, including BridgeBio’s acoramidis and Prothena’s birtamimab. Germany’s AMNOG assessments granted “considerable additional benefit” ratings to daratumumab and vutrisiran, locking in premium price corridors without confidential rebates. Realtime outcome registries reinforce the market: Sweden’s SwedAC tracked 94 percent of national ATTR-CM patients, feeding data that support continuous reimbursement renewal and pharmaco-economic validation.

Asia Pacific

Asia Pacific is the fastest-growing geography in the amyloidosis therapeutics market, propelled by simultaneous gains in diagnosis, disposable income, and regulatory flexibility. China’s National Rare Disease list inclusion in 2023 unlocked centralized procurement, triggering 6,300 AL and 5,100 ATTR treatment initiations that year. Japan’s health system processed 12,300 cardiac PYP scans and 9,800 TTR gene tests, doubling its managed patient pool and driving 4,080 patisiran vials into hospitals such as Juntendo and Osaka University. India is following suit: five new amyloid clinics inside the All India Institute network screened 2,400 cases and secured government funding for 7,200 generic bortezomib cycles. Regional policy tailwinds matter—China’s Hainan Boao pilot zone granted early access to acoramidis for 260 patients, and Australia’s Life Saving Drugs Program added vutrisiran in February 2024 with annual subsidies exceeding 68,000 US dollars per course. Venture capital is responding: Singapore-based ClavystBio led a 60-million-dollar series-B round for RNAi start-up Carmine Therapeutics, one of 19 pipeline projects now recruiting across Asia.

Top Companies in the Amyloidosis Therapeutics Market

• Astra Zeneca
• Alnylam Pharmaceuticals, Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• GSK plc.
• Takeda Pharmaceutical Company Limited
• Sanofi, Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Novartis AG
• Ionis Pharmaceuticals
• Other Prominent Players

Market Segmentation Overview

By Therapy Type

• Chemotherapy
• Stem Cell Transplantation
• Targeted Therapy
• Supportive Care & Surgery
• Others

By Route of Administration

• Oral
• Intravenous
• Subcutaneous

By Indication

• AL Amyloidosis
• ATTR Amyloidosis
• AA Amyloidosis
• Wild-Type ATTR

By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Home Care Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
    • Indonesia
    • Thailand
    • Singapore
    • Vietnam
    • Malaysia
    • Philippines
    • Rest of ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America